Search clinical trials for: BIIB100

Total 74 results

NightstaRx Ltd, a Biogen Company

Enrolling by invitation

Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa (SOLSTICE)

Choroideremia | X-Linked Retinitis Pigmentosa

United States, United Kingdom, Netherlands, Germany, France, Brazil, Canada, Denmark, Finland
Biogen

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adults With Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis

United States
Biogen

Completed

A Study to Evaluate the Relative Bioavailability of Two Formulations of BIIB104 and Assess the Effect of Food on the Pharmacokinetics of BIIB104 Following Administration of a Single, Fixed, Oral Dose of BIIB104 in Healthy Participants

Healthy Volunteers

United States
Biogen

Completed

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIIB107 in Healthy Adult Participants

Healthy Volunteers

United States
Biogen

Active, not recruiting

A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation (ALSpire)

Amyotrophic Lateral Sclerosis

United States, Netherlands, Italy, Canada
Biogen

Completed

A Study to Explore Pharmacodynamic Effects of BIIB104 on Brain Circuitry in Healthy Participants

Healthy Volunteers

United Kingdom
Biogen

Completed

A Study to Evaluate Safety and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese Participants

Healthy Volunteer

United States
Braintree Laboratories

Completed

A Safety and Efficacy Evaluation of Topical Treatments for Moderate-Severe Facial Acne Vulgaris

Acne Vulgaris

United States
Biogen

Completed

A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) (TALLY)

Cognitive Impairment Associated With Schizophrenia

Spain, United States, Germany, Japan, United Kingdom
Biogen

Terminated

A Pharmacokinetics and Safety Study of BIIB132 in Adults With Spinocerebellar Ataxia 3

Spinocerebellar Ataxia Type 3

United States, Netherlands, Israel, Portugal, United Kingdom, Germany
Braintree Laboratories

Completed

BLI1100-202: BLI1100 for the Treatment of Moderate to Severe Acne Vulgaris

Acne Vulgaris

United States
Biogen

Completed

Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB104 in Healthy Japanese and Non-Japanese Participants

Healthy Volunteers

United States
Biogen

Recruiting

A Study to Evaluate the Pharmacokinetics, Safety and Immunogenicity of BIIB800 Subcutaneously (SC) Compared to Actemra® in Healthy Male Participants

Healthy Volunteer

United States
Biogen

Recruiting

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB115

Healthy Volunteer | Muscular Atrophy, Spinal

Korea, Republic of, Germany, Belgium, Netherlands, France, Italy, Poland, Canada, United Kingdom, Israel
Biogen

Recruiting

A Study to Learn About the Safety of BIIB080 and Whether it Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age (CELIA)

Mild Cognitive Impairment Due to Alzheimer's Disease | Alzheimer's Disease Dementia

Belgium, United States, Australia, Italy, Spain, Denmark, United Kingdom, Czechia, France, Poland, Switzerland, Germany, Canada, Japan, Finland, Netherlands, Sweden
Biogen
Denali Therapeutics Inc.

Completed

A Study to Determine the Absolute Bioavailability of BIIB122/DNL151 in Healthy Subjects

Healthy Volunteers

United States
Biogen
Denali Therapeutics Inc.

Recruiting

A Study to Assess the Safety of BIIB122 Tablets and if it Can Slow the Worsening of Early-Stage Parkinson's Disease in Participants Between the Ages of 30 and 80 (LUMA)

Parkinson Disease

United States, Netherlands, Italy, Spain, Israel, Canada, China, Germany, France, Austria, United Kingdom, Poland, Japan
Biogen
Denali Therapeutics Inc.

Terminated

A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (LIGHTHOUSE)

Parkinson Disease

United States, Italy, Spain, Germany, France, United Kingdom
Biogen

Completed

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics, With Target Occupancy Study of BIIB113 in Healthy Participants

Healthy Volunteer

United Kingdom, Sweden
Braintree Laboratories

Enrolling by invitation

A Study to Evaluate the Long-Term Safety of BLI5100 in Patients With Gastroesophageal Reflux Disease

Non-erosive Reflux Disease | Erosive Esophagitis

United States
Braintree Laboratories

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Non-Erosive Reflux Disease

Non-erosive Reflux Disease

United States
Biogen

Completed

A Study to See How BIIB122 Works in the Human Body, and to Evaluate it's Safety, and Tolerability in Healthy Adult Japanese, Chinese, and Caucasian Participants

Healthy Volunteer

United States
Biogen

Withdrawn

A Study to Evaluate the Efficacy and Safety of BIIB131 for Participants With Ischemic Stroke Between 4.5 and 24 Hours After Last Known Well (DAISY)

Ischemic Stroke
Braintree Laboratories

Recruiting

A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Erosive Esophagitis

Erosive Esophagitis

United States
Biogen

Completed

A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112 (XIRIUS)

X-Linked Retinitis Pigmentosa

United States, United Kingdom
Biogen

Completed

Efficacy and Safety of BIIB111 for the Treatment of Choroideremia (STAR)

Choroideremia

United States, Finland, France, Denmark, Netherlands, Germany, United Kingdom, Canada
NightstaRx Ltd, a Biogen Company

Completed

Natural History of the Progression of X-Linked Retinitis Pigmentosa (XOLARIS)

X-Linked Retinitis Pigmentosa

United States, France, United Kingdom, Finland, Netherlands, Germany, Canada
Braintree Laboratories

Completed

BLI1100 for the Treatment of Moderate to Severe Acne Vulgaris

Acne Vulgaris

United States
Biogen
Denali Therapeutics Inc.

Completed

A Study of Mass Balance, Pharmacokinetics, Metabolite Profile, and Metabolite Identification of BIIB122/DNL151 in Healthy Male Subjects

Healthy Volunteers

United States
Biogen

Completed

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB133 (Dapirolizumab Pegol) in Healthy Japanese and Caucasian Participants

Healthy Volunteers

United States
Biogen

Completed

Pharmacokinetic Study of Peginterferon Beta-1a in Japanese and Caucasian Adult Healthy Participants.

Healthy

United Kingdom
Biogen

Completed

A Phase I Study of BIIB015 in Relapsed/Refractory Solid Tumors

Solid Tumors

United States
Biogen

Completed

A Safety Study of Retinal Gene Therapy for Choroideremia With Administration of BIIB111 (GEMINI)

Choroideremia

United States, Germany, France
Biogen

Completed

Peginterferon Beta-1a (BIIB017) Autoinjector Pharmacokinetic Study in Healthy Volunteers

Multiple Sclerosis | Healthy

United States
Biogen

Completed

Safety, Tolerability and Pharmacokinetics of BIIB118 (PF-05251749)

Healthy

United States
Sage Therapeutics
Biogen

Recruiting

Zuranolone Pharmacokinetics (PK) and Safety Study Adolescent Participants With Major Depressive Disorder (MDD)

Major Depressive Disorder

United States
Biogen

Completed

A Single-Dose, Pharmacokinetic/Pharmacodynamic (PK/PD), & Safety Study of BIIB017 in Participants With Renal Impairment & Healthy Volunteers

Healthy | Renal Insufficiency
Biogen

Completed

Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers

Multiple Sclerosis

United States
Biogen
AbbVie

Terminated

Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab (SUSTAIN)

Relapsing-Remitting Multiple Sclerosis (RRMS)

Italy, United States, Canada, Germany, Puerto Rico
Biogen

Active, not recruiting

A Study to Assess the Potential for Gastric-pH Dependent Drug-Drug Interactions of BIIB122 With a Proton Pump Inhibitor in Healthy Participants

Healthy Volunteer

United States
Biogen
AbbVie

Completed

Daclizumab Japanese PK Study

Healthy

United Kingdom
Biogen
AbbVie

Terminated

Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019 (EXTEND)

Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis

United States, Denmark, Italy, United Kingdom, Czechia, Canada, Hungary, Spain, Australia, Israel, Georgia, Serbia, Russian Federation, Ukraine, India, Poland, Brazil, France, Argentina, Germany, Greece, Ireland, Mexico, Moldova, Republic... and more
Biogen

Completed

BIIB014 Cardiovascular Monitoring Study

Healthy

United States
Biogen
AbbVie

Completed

Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis (SELECT)

Relapsing-Remitting Multiple Sclerosis

Czech Republic, Poland, Russian Federation, United Kingdom, Hungary, Ukraine, Germany, India
Biogen
AbbVie

Completed

Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis (SELECTION)

Relapsing-Remitting Multiple Sclerosis

Czech Republic, Poland, Russian Federation, United Kingdom, Hungary, Ukraine, Germany, India
Biogen

Completed

Biogen Multiple Sclerosis Pregnancy Exposure Registry

Multiple Sclerosis | Exposure During Pregnancy

Spain, Italy, Australia, Poland, United Kingdom, United States, Canada, France, Germany, Ireland
Biogen

Terminated

Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants

Multiple Sclerosis, Relapsing-Remitting

Mexico, Turkey, United States, Hungary, Taiwan, Thailand, Korea, Republic of, Saudi Arabia, Malaysia, Colombia, Estonia, Jordan, Tunisia
Biogen
AbbVie

Completed

Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis (SELECTED)

Relapsing-Remitting Multiple Sclerosis

Germany, Hungary, Czechia, Russian Federation, India, Poland, Ukraine, United Kingdom
Biogen

Completed

Multiple Dose Study Of BIIB118 (PF-05251749) In Healthy Volunteers

Healthy Adult Subjects | Healthy Elderly Subjects

United States
Knopp Biosciences
Biogen

Terminated

Phase 3 Extension Study of Dexpramipexole in ALS (ENVISION)

Amyotrophic Lateral Sclerosis

United States, United Kingdom, Netherlands, Spain, Belgium, Germany, Australia, Sweden, France, Ireland, Canada

3

Subscribe